NASDAQ:LMNX

Luminex Competitors

$32.95
+0.67 (+2.08 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.12
Now: $32.95
$33.29
50-Day Range
$26.50
MA: $31.84
$34.13
52-Week Range
$20.61
Now: $32.95
$41.69
Volume436,107 shs
Average Volume633,048 shs
Market Capitalization$1.56 billion
P/E Ratio84.49
Dividend Yield1.24%
Beta0.61

Competitors

Luminex (NASDAQ:LMNX) Vs. TMO, ILMN, A, MTD, WAT, and BIO

Should you be buying LMNX stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Luminex, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Rad Laboratories (BIO).

Thermo Fisher Scientific (NYSE:TMO) and Luminex (NASDAQ:LMNX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 88.1% of Luminex shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 9.4% of Luminex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Thermo Fisher Scientific and Luminex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
Luminex4.60%3.75%2.73%

Earnings and Valuation

This table compares Thermo Fisher Scientific and Luminex's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.38$3.70 billion$12.3538.78
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90

Thermo Fisher Scientific has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Thermo Fisher Scientific and Luminex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific031702.85
Luminex00103.00

Thermo Fisher Scientific currently has a consensus target price of $526.3684, suggesting a potential upside of 9.92%. Luminex has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Given Luminex's stronger consensus rating and higher probable upside, analysts clearly believe Luminex is more favorable than Thermo Fisher Scientific.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Dividends

Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Luminex pays an annual dividend of $0.40 per share and has a dividend yield of 1.2%. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Luminex pays out -190.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has raised its dividend for 3 consecutive years and Luminex has raised its dividend for 1 consecutive years. Luminex is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Thermo Fisher Scientific beats Luminex on 10 of the 17 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Luminex and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
Illumina19.70%15.93%10.09%

Volatility and Risk

Luminex has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Luminex and Illumina, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex00103.00
Illumina48602.11

Luminex currently has a consensus target price of $38.00, indicating a potential upside of 15.33%. Illumina has a consensus target price of $370.5789, indicating a potential downside of 8.13%. Given Luminex's stronger consensus rating and higher possible upside, equities research analysts plainly believe Luminex is more favorable than Illumina.

Insider & Institutional Ownership

88.1% of Luminex shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 9.4% of Luminex shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Luminex and Illumina's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90
Illumina$3.54 billion16.61$1.00 billion$6.5761.40

Illumina has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Luminex on 11 of the 14 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Luminex and Agilent Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex00103.00
Agilent Technologies081902.70

Luminex currently has a consensus price target of $38.00, indicating a potential upside of 15.33%. Agilent Technologies has a consensus price target of $104.70, indicating a potential downside of 20.63%. Given Luminex's stronger consensus rating and higher possible upside, equities analysts plainly believe Luminex is more favorable than Agilent Technologies.

Institutional & Insider Ownership

88.1% of Luminex shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

Luminex pays an annual dividend of $0.40 per share and has a dividend yield of 1.2%. Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Luminex pays out -190.5% of its earnings in the form of a dividend. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Luminex has increased its dividend for 1 consecutive years and Agilent Technologies has increased its dividend for 1 consecutive years. Luminex is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Luminex and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
Agilent Technologies13.47%21.02%10.73%

Risk and Volatility

Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Earnings and Valuation

This table compares Luminex and Agilent Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90
Agilent Technologies$5.34 billion7.53$719 million$3.2840.22

Agilent Technologies has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats Luminex on 9 of the 16 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Luminex (NASDAQ:LMNX) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Comparatively, 9.4% of Luminex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mettler-Toledo International and Luminex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International35101.78
Luminex00103.00

Mettler-Toledo International presently has a consensus target price of $971.3750, suggesting a potential downside of 20.54%. Luminex has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Given Luminex's stronger consensus rating and higher probable upside, analysts clearly believe Luminex is more favorable than Mettler-Toledo International.

Profitability

This table compares Mettler-Toledo International and Luminex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
Luminex4.60%3.75%2.73%

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Mettler-Toledo International and Luminex's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion9.48$561.11 million$22.7753.69
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90

Mettler-Toledo International has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Luminex on 9 of the 13 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Waters (NYSE:WAT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Profitability

This table compares Luminex and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
Waters22.61%-349.31%21.11%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Luminex and Waters, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex00103.00
Waters48101.77

Luminex presently has a consensus price target of $38.00, suggesting a potential upside of 15.33%. Waters has a consensus price target of $224.20, suggesting a potential downside of 27.00%. Given Luminex's stronger consensus rating and higher possible upside, analysts plainly believe Luminex is more favorable than Waters.

Insider and Institutional Ownership

88.1% of Luminex shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 9.4% of Luminex shares are owned by company insiders. Comparatively, 1.5% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Luminex and Waters' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90
Waters$2.41 billion7.92$592.20 million$8.9934.16

Waters has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Summary

Waters beats Luminex on 8 of the 13 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Luminex (NASDAQ:LMNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Bio-Rad Laboratories and Luminex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
Luminex4.60%3.75%2.73%

Analyst Recommendations

This is a summary of current recommendations and price targets for Bio-Rad Laboratories and Luminex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00303.00
Luminex00103.00

Bio-Rad Laboratories presently has a consensus price target of $700.00, indicating a potential upside of 16.17%. Luminex has a consensus price target of $38.00, indicating a potential upside of 15.33%. Given Bio-Rad Laboratories' higher probable upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Luminex.

Institutional & Insider Ownership

63.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 27.5% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 9.4% of Luminex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Luminex's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.78$1.76 billion$7.0685.35
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90

Bio-Rad Laboratories has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Rad Laboratories beats Luminex on 11 of the 13 factors compared between the two stocks.


Luminex Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.1$478.88+1.5%$188.58 billion$25.54 billion39.25News Coverage
Illumina logo
ILMN
Illumina
1.6$403.37+0.1%$58.85 billion$3.54 billion93.59Analyst Report
Insider Selling
Agilent Technologies logo
A
Agilent Technologies
1.8$131.91+0.9%$40.19 billion$5.34 billion57.35
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,222.41+1.3%$28.51 billion$3.01 billion51.43
Waters logo
WAT
Waters
1.3$307.14+1.0%$19.06 billion$2.41 billion38.25
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$602.57+1.7%$17.98 billion$2.31 billion5.16News Coverage
Bio-Techne logo
TECH
Bio-Techne
2.0$408.72+0.9%$15.86 billion$738.69 million65.40Analyst Downgrade
News Coverage
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$306.40+0.4%$15.38 billion$2.62 billion51.07Analyst Upgrade
Insider Selling
News Coverage
PerkinElmer logo
PKI
PerkinElmer
1.9$133.39+1.4%$14.95 billion$2.88 billion36.25
Bruker logo
BRKR
Bruker
1.9$68.61+1.7%$10.40 billion$2.07 billion67.27Gap Up
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$32.16+4.1%$6.21 billion$90.89 million-114.85Gap Down
Fluidigm logo
FLDM
Fluidigm
1.8$4.60+2.4%$342.92 million$117.24 million-6.87
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.53+0.3%$260.06 million$116.18 million-36.28Analyst Upgrade
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.50+4.0%$72.05 million$420,000.00-1.69Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.